Cuenca Hospital Develops New Cat Allergy Vaccine Based on Immunotherapy
The Allergology Service at the University Hospital of Cuenca has developed a new vaccine for people allergic to cats, built on an immunotherapy strategy designed to change how the immune system responds to cat proteins.
The department presented the work for the first time in Spain in late October at the Spanish Society of Allergology and Clinical Immunology’s international symposium, a four-day event in Gran Canaria that ran from October 28 to 31, 2026.
Dr. Antonio Moreno, head of the hospital’s Allergology Service, presented the findings at the symposium before more than 1,100 allergy specialists from around the world, according to Lacerca. The Castilla-La Mancha regional health service, which runs the hospital, confirmed the presentation in a press statement and described the work as placing Cuenca “on the map of medical research and innovation” in allergology, according to Telecinco.
Key Clinical Takeaways:
- A team at the University Hospital of Cuenca has developed a vaccine for cat allergy based on specific immunotherapy, presented for the first time in Spain at an international SEAIC symposium in Gran Canaria.
- The treatment aims to retrain the immune response to cat allergens rather than only control symptoms with medication — a different goal from antihistamines and other symptomatic drugs.
- No efficacy data, safety profile, dosing schedule or availability date has been released, so this remains a research advance, not a treatment patients can request.
A vaccine that retrains the immune system
Cat allergy is driven mainly by proteins found in the animal’s skin, saliva and secretions. In a sensitized patient, the immune system treats those proteins as a threat and mounts a disproportionate response, producing rhinitis, conjunctivitis and asthma; in some cases the sources describe the symptoms as considerably limiting quality of life.
Specific immunotherapy, Moreno explained, is one of the most relevant therapeutic tools in modern allergology because it seeks to modify the immune system’s response to the allergen responsible, going beyond purely pharmacological control of symptoms. Conventional anti-allergy vaccines work on the same principle: controlled exposure to allergen preparations to build tolerance, with effectiveness varying by allergy type, preparation and patient.

What the presentation does and does not establish
The symposium presentation confirms development of a new therapeutic proposal. It does not establish that the vaccine is authorized for sale or ready for routine administration. The regional government’s statement said nothing about the composition of the preparation, its route of administration, the number of doses, the length of treatment or the degree of improvement observed in participants.
The Folio, a Spanish outlet that covered the same presentation, drew the same conclusion and went further than the press release: no availability date has been announced and no detailed efficacy or safety results have been made public, so patients cannot request the treatment yet. It also said that meaningful conclusions will require published results showing whether the new vaccine offers advantages over immunotherapies already in use.
The Castilla-La Mancha health service framed the study as evidence of the scientific and care potential of the provincial hospital. Moreno called the international presentation a recognition of the work of the hospital’s Allergology Service and a marker of the capacity of Cuenca’s health professionals to contribute to advances that can transform allergy treatment.
Cuenca’s case for a research role
The department is already positioned as a clinical research site. Specialists who join the Allergology Service take part in seven multicenter clinical trials, according to the regional government’s statement — a portfolio the hospital presents as consolidating its standing as a reference center for developing new therapies in allergic disease.

That matters for patients because trial networks are how emerging allergy treatments move from laboratory findings to accredited clinical practice.
Many allergists across Spain run or participate in similar studies, and people whose cat allergy is not controlled with first-line antihistamines or nasal therapy can ask a board-certified allergist whether they might qualify for an immunotherapy trial — the Society of Allergology and Clinical Immunology maintains clinical resources and specialist listings for exactly this kind of question.
Immunotherapy for cat allergy builds on existing work
Cat immunotherapy is not a blank slate. Subcutaneous and sublingual immunotherapy against cat allergens already exist in European clinical practice, and the scientific literature on the most characterized cat allergen — the Fel d 1 protein, documented in peer-reviewed databases such as PubMed — spans decades of allergen characterization and tolerance-induction research. The novelty Cuenca is claiming lies in its specific immunotherapy strategy, about which the released information gives no technical specifics.
The World Health Organization’s allergic disease materials list allergic rhinitis and asthma among the most common chronic conditions worldwide, which is the clinical context a cat-specific vaccine targets: reducing morbidity in a patient group currently managed largely with symptomatic drugs and allergen avoidance.
What has to happen before patients see it
The open questions, as the reporting stands: peer-reviewed publication of results, a defined efficacy and safety profile, regulatory evaluation, and an announced timeline for availability. None of the four outlets covering the presentation — Telecinco, La Cerca, 20minutos or The Folio — reports a date for any of those steps. The Folio stated plainly that the advance “is not a treatment that patients can request immediately.”
Until those results appear, the standard of care for cat allergy remains established symptomatic pharmacology and, where appropriate, existing specific immunotherapy prescribed after diagnosis by an allergy specialist. Patients whose symptoms include asthma flares triggered by cat exposure should be evaluated by a physician, since uncontrolled asthma carries measurable risk, and managing it well is the precondition for any tolerance-inducing treatment.
Moreno’s team participates in seven multicenter trials, and the next concrete milestone for this vaccine will be whatever the department publishes next — the seven-trial portfolio already in place is the vehicle through which those results are expected to arrive.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
- Children’s Diets Frequently Lack Essential Dietary Fiber
- Google Detects First AI Cyberattacks Running Full Intrusion Chain, Human Still Involved
- Chinese CDC Researchers Compare Influenza and COVID-19 Etiology, Pathogenesis, Vaccine and Antiviral Development (archyde.com)
- Study Finds Malaria Antibody L9LS Blunts R21 Vaccine Response (time.news)